Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) is considered a potential target for the treatment of type II diabetes and obesity due to its critical negative role in the insulin signaling pathway.
|
30729132 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that PTPN1 SNPs associated with BC susceptibility in Chinese females, which also suggested a novel mechanism between obesity, diabetes mellitus, and BC risk.
|
30805963 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Protein-tyrosine phosphatase 1B (PTP1B), a validated therapeutic target for diabetes and obesity, also plays a critical positive or negative role in tumorigenesis.
|
31745071 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) has led to an intense interest in developing its inhibitors as anti-diabetes, anti-obesity and anti-cancer agents.
|
30704618 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) is a major negative regulator of both the insulin and leptin receptor phosphorylation which impacts insulin sensitivity and hence is a major therapeutic target for the treatment of type 2 diabetes and obesity.
|
31451955 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings causally link heightened hypothalamic PTP1B and TCPTP with leptin and insulin resistance and the maintenance of obesity and define a viable pharmacological approach by which to promote weight loss in obesity.
|
31509751 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B), a key negative regulator in insulin signaling pathways, is regarded as a potential target for the treatment of type II diabetes and obesity.
|
30238851 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) has been considered as a promising therapeutic target for type 2 diabetes mellitus (T2DM) and obesity due to its key regulating effects in insulin signaling and leptin receptor pathways.
|
30611982 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) acts as a negative regulator of insulin and leptin signalling and is crucially involved in the development of type 2 diabetes mellitus, obesity, cancer and neurodegenerative diseases.
|
31491569 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B), a key negative regulator of insulin signaling, is considered as a promising and validated therapeutic target for type 2 diabetes mellitus (T2DM) and obesity.
|
31539748 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Aberrant PTP1B is associated with obesity, diabetes, cancers, and neurodegenerative disorders.
|
29235148 |
2018 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase1B (PTP1B), a significant negative regulator in insulin and leptin signaling pathways, has emerged as a promising drug target for Type II diabetes mellitus and obesity.
|
30273014 |
2018 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) is an important therapeutic target for type II diabetes and obesity because of its pivotal role as a negative modulator in both insulin and leptin signalling pathways.
|
28228082 |
2018 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, since PTP1B may be a therapeutic target for both T2DM and obesity, the search for novel and promising natural inhibitors has gained much attention.
|
30558294 |
2018 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cratoxylum cochinchinense displayed significant inhibition against protein tyrosine phosphatase 1B (PTP1B) and α-glucosidase, both of which are key target enzymes to attenuate diabetes and obesity.
|
29306546 |
2018 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
PTP1B serving as a key negative regulator of insulin signaling is a novel target for type 2 diabetes and obesity.
|
29289892 |
2018 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that PTP1B and TCPTP in the ARC are essential for celastrol's weight lowering effects in adult obese mice.
|
30525586 |
2018 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B), a negative modulator of insulin and cytokine signaling, is a therapeutic target for type 2 diabetes and obesity.
|
29126873 |
2018 |
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PTP1B activity was lower in OB-VAT treated with PCA with respect to untreated (p < 0.05).
|
29769704 |
2018 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hence, inhibition of PTP1B may help prevent and reduce obesity.
|
30383868 |
2018 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) is a potential drug target for diabetes and obesity.
|
30024103 |
2018 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
In insulin and leptin signaling pathway, Protein-Tyrosine Phosphatase 1B (PTP1B) plays a crucial controlling role as a negative regulator, which makes it an attractive therapeutic target for both Type-2 Diabetes (T2D) and obesity.
|
28006676 |
2017 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) is a well-known inhibitor of insulin signaling pathways and inhibitors against PTP1B are being developed as promising drug candidates for treatment of obesity.
|
28492548 |
2017 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) is a known regulator of the insulin and leptin signaling pathways and is an active target for the design of inhibitors for the treatment of type II diabetes and obesity.
|
27959494 |
2017 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, the present study highlights the deleterious role that the amygdalar PTP1B has on energy homeostasis in obesity states.
|
28403933 |
2017 |